These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 31332252)

  • 1. An oligo-His-tag of a targeting module does not influence its biodistribution and the retargeting capabilities of UniCAR T cells.
    Jureczek J; Bergmann R; Berndt N; Koristka S; Kegler A; Puentes-Cala E; Soto JA; Arndt C; Bachmann M; Feldmann A
    Sci Rep; 2019 Jul; 9(1):10547. PubMed ID: 31332252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology "UniCAR".
    Feldmann A; Arndt C; Bergmann R; Loff S; Cartellieri M; Bachmann D; Aliperta R; Hetzenecker M; Ludwig F; Albert S; Ziller-Walter P; Kegler A; Koristka S; Gärtner S; Schmitz M; Ehninger A; Ehninger G; Pietzsch J; Steinbach J; Bachmann M
    Oncotarget; 2017 May; 8(19):31368-31385. PubMed ID: 28404896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous targeting of prostate stem cell antigen and prostate-specific membrane antigen improves the killing of prostate cancer cells using a novel modular T cell-retargeting system.
    Arndt C; Feldmann A; Koristka S; Cartellieri M; Dimmel M; Ehninger A; Ehninger G; Bachmann M
    Prostate; 2014 Sep; 74(13):1335-46. PubMed ID: 25053443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended half-life target module for sustainable UniCAR T-cell treatment of STn-expressing cancers.
    Loureiro LR; Feldmann A; Bergmann R; Koristka S; Berndt N; Máthé D; Hegedüs N; Szigeti K; Videira PA; Bachmann M; Arndt C
    J Exp Clin Cancer Res; 2020 May; 39(1):77. PubMed ID: 32370811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts.
    Cartellieri M; Feldmann A; Koristka S; Arndt C; Loff S; Ehninger A; von Bonin M; Bejestani EP; Ehninger G; Bachmann MP
    Blood Cancer J; 2016 Aug; 6(8):e458. PubMed ID: 27518241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. UniCAR T-Cell Potency-A Matter of Affinity between Adaptor Molecules and Adaptor CAR T-Cells?
    Boutier H; Loureiro LR; Hoffmann L; Arndt C; Bartsch T; Feldmann A; Bachmann MP
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice.
    Hillerdal V; Ramachandran M; Leja J; Essand M
    BMC Cancer; 2014 Jan; 14():30. PubMed ID: 24438073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cells.
    Koristka S; Ziller-Walter P; Bergmann R; Arndt C; Feldmann A; Kegler A; Cartellieri M; Ehninger A; Ehninger G; Bornhäuser M; Bachmann MP
    Cancer Immunol Immunother; 2019 Sep; 68(9):1401-1415. PubMed ID: 31414180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel nanobody-based target module for retargeting of T lymphocytes to EGFR-expressing cancer cells via the modular UniCAR platform.
    Albert S; Arndt C; Feldmann A; Bergmann R; Bachmann D; Koristka S; Ludwig F; Ziller-Walter P; Kegler A; Gärtner S; Schmitz M; Ehninger A; Cartellieri M; Ehninger G; Pietzsch HJ; Pietzsch J; Steinbach J; Bachmann M
    Oncoimmunology; 2017; 6(4):e1287246. PubMed ID: 28507794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. "UniCAR"-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells.
    Mitwasi N; Feldmann A; Arndt C; Koristka S; Berndt N; Jureczek J; Loureiro LR; Bergmann R; Máthé D; Hegedüs N; Kovács T; Zhang C; Oberoi P; Jäger E; Seliger B; Rössig C; Temme A; Eitler J; Tonn T; Schmitz M; Hassel JC; Jäger D; Wels WS; Bachmann M
    Sci Rep; 2020 Feb; 10(1):2141. PubMed ID: 32034289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Redirection of CD4+ and CD8+ T lymphocytes via a novel antibody-based modular targeting system triggers efficient killing of PSCA+ prostate tumor cells.
    Arndt C; Feldmann A; Töpfer K; Koristka S; Cartellieri M; Temme A; Ehninger A; Ehninger G; Bachmann M
    Prostate; 2014 Sep; 74(13):1347-58. PubMed ID: 25053504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multivalent adaptor proteins specifically target NK cells carrying a universal chimeric antigen receptor to ErbB2 (HER2)-expressing cancers.
    Pfeifer Serrahima J; Zhang C; Oberoi P; Bodden M; Röder J; Arndt C; Feldmann A; Kiefer A; Prüfer M; Kühnel I; Tonn T; Bachmann M; Wels WS
    Cancer Immunol Immunother; 2023 Sep; 72(9):2905-2918. PubMed ID: 36688995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells.
    Mitwasi N; Feldmann A; Bergmann R; Berndt N; Arndt C; Koristka S; Kegler A; Jureczek J; Hoffmann A; Ehninger A; Cartellieri M; Albert S; Rossig C; Ehninger G; Pietzsch J; Steinbach J; Bachmann M
    Oncotarget; 2017 Dec; 8(65):108584-108603. PubMed ID: 29312553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retargeting of UniCAR T cells with an
    Bachmann D; Aliperta R; Bergmann R; Feldmann A; Koristka S; Arndt C; Loff S; Welzel P; Albert S; Kegler A; Ehninger A; Cartellieri M; Ehninger G; Bornhäuser M; von Bonin M; Werner C; Pietzsch J; Steinbach J; Bachmann M
    Oncotarget; 2018 Jan; 9(7):7487-7500. PubMed ID: 29484126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity.
    Murad JP; Tilakawardane D; Park AK; Lopez LS; Young CA; Gibson J; Yamaguchi Y; Lee HJ; Kennewick KT; Gittins BJ; Chang WC; Tran CP; Martinez C; Wu AM; Reiter RE; Dorff TB; Forman SJ; Priceman SJ
    Mol Ther; 2021 Jul; 29(7):2335-2349. PubMed ID: 33647456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR.
    Arndt C; Feldmann A; Koristka S; Schäfer M; Bergmann R; Mitwasi N; Berndt N; Bachmann D; Kegler A; Schmitz M; Puentes-Cala E; Soto JA; Ehninger G; Pietzsch J; Liolios C; Wunderlich G; Kotzerke J; Kopka K; Bachmann M
    Oncoimmunology; 2019; 8(11):1659095. PubMed ID: 31646084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The UniCAR system: A modular CAR T cell approach to improve the safety of CAR T cells.
    Bachmann M
    Immunol Lett; 2019 Jul; 211():13-22. PubMed ID: 31091431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FLT3-directed UniCAR T-cell therapy of acute myeloid leukaemia.
    Peschke JC; Bergmann R; Mehnert M; Gonzalez Soto KE; Loureiro LR; Mitwasi N; Kegler A; Altmann H; Wobus M; Máthé D; Szigeti K; Feldmann A; Bornhäuser M; Bachmann M; Fasslrinner F; Arndt C
    Br J Haematol; 2023 Sep; 202(6):1137-1150. PubMed ID: 37460273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy.
    Töpfer K; Cartellieri M; Michen S; Wiedemuth R; Müller N; Lindemann D; Bachmann M; Füssel M; Schackert G; Temme A
    J Immunol; 2015 Apr; 194(7):3201-12. PubMed ID: 25740942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.